COG ADVL0314: A PHASE 1 STUDY OF BEVACIZUMAB IN REFRACTORY SOLID TUMORS

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。这项I期研究测试了一种名为贝伐单抗的新实验药物的安全性，贝伐单抗是一种抗体，可以阻止新血管的发育。如果没有新形成的血管的血液供应，肿瘤就不能生长，用贝伐单抗进行的实验室实验表明，它可能会阻止新血管的生长。当暴露于贝伐单抗时，肿瘤可能无法生长。贝伐单抗的安全剂量已经在成人中发现，但还没有在儿童中进行贝伐单抗的试验。这项研究的目的是测试贝伐单抗的安全性，看看它对儿童和儿童癌症有什么影响（好的和坏的），并找到最高剂量的贝伐单抗可以给儿童而不会引起严重的副作用。这项研究的其他目标是了解身体如何处理药物，并更好地了解肿瘤细胞与健康细胞不同的功能。由于这项I期试验的主要目的是寻找可以安全地给予儿童的贝伐单抗的最大剂量，因此有些患者接受的剂量可能太少，对他们的肿瘤没有任何影响，或者可能太高，导致不良的副作用。目前尚不清楚该药物在任何剂量下是否能有效治疗本研究中接受治疗的患者的癌症。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This phase I study tests the safety of a new experimental drug called bevacizumab, which is an antibody that works to block the development of new blood vessels. Tumors cannot grow without blood supply through newly formed blood vessels, and laboratory experiments performed with bevacizumab showed that it may block the growth of new blood vessels. Tumors may not be able to grow when exposed to bevacizumab. A safe dose of bevacizumab has already been found in adults, but there have been no trials of bevacizumab in children yet. The goals of this study are to test the safety of bevacizumab, to see what effects (good and bad) it has on children and children's cancer, and to find the highest dose of bevacizumab that can be given to children without causing severe side effects. Other goals of this study are to learn how the body handles the drug, and to better understand the functions in tumor cells that differ from healthy cells. Because the main purpose of this phase I trial is to find the maximum dose of bevacizumab that can be safely given to children, the dose that some patients receive may be too little to have any effect on their tumor, or it may be too high and cause bad side effects. It is not known if this drug, at any dose, will be effective in treating the cancer of patients treated on this study.